ThromboGenics Presenting New Research Findings at the European Association for Vision and Eye Research (EVER) Congress in Nice

5 Oct 2016

Leuven, Belgium - ThromboGenics NV today announces that the Company will be presenting two scientific posters at the upcoming European Association for Vision and Eye Research (EVER) Annual Meeting. The Meeting is being held from October 5th – 8th in Nice, France.

  • Dr Tjing-Tjing Hu, from ThromboGenics will present a poster entitled: Quantitative assessment of retinal permeability in the diabetic Akimba mouse. The outcome of the study highlights the in vivo efficacy of anti-PlGF treatment in Akimba, and confirms its potential as a promising next-generation therapeutic for diabetic retinopathy (DR)/ diabetic macular edema (DME).
  • Dr Michael Porcu and colleagues from ThromboGenics will present a poster entitled: Mechanisms of ocriplasmin uptake by retinal cells. The data indicate that cultured Müller and RPE cells can eliminate ocriplasmin from the retina. The cellular elimination pathway involves primarily Rab7-positive endosomes in both Müller and RPE cells.

For more information on the above mentioned subjects, please go the research page of the ThromboGenics website.

Dr. Patrik De Haes, ThromboGenics' CEO, said: "ThromboGenics is committed to high-quality fundamental research in the field of ophthalmology as demonstrated by these posters to be presented at the upcoming EVER conference. It is this type of research that allows us to discover and advance the development of our products pipeline, targeting both DR and DME, which are significant indications where there are clear unmet medical needs."